1-5 of 5
William G. Rice
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Luxeptinib (CG-806) targets FLT3 and clusters of kinases operative in acute myeloid leukemia

William G. Rice, Stephen B. Howell, Hongying Zhang, Nasrin Rastgoo, Andrea Local, Stephen E. Kurtz, Pierrette Lo, Daniel Bottomly, Beth Wilmot, Shannon K. McWeeney, Brian J. Druker, Jeffrey W. Tyner
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther molcanther.0832.2021.
DOI: https://doi.org/10.1158/1535-7163.MCT-21-0832
Published: 02 May 2022
View article
PDF
Includes: Supplementary data
Journal Articles

APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency

Cheng-Yu Tsai, Si Sun, Hongying Zhang, Andrea Local, Yongxuan Su, Larry A. Gross, William G. Rice, Stephen B. Howell
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (6): 1167–1176.
DOI: https://doi.org/10.1158/1535-7163.MCT-17-0834
Published: 31 May 2018
View article
PDF
Includes: Supplementary data
Journal Articles

APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells

Andrea Local, Hongying Zhang, Khalid D. Benbatoul, Peter Folger, Xia Sheng, Cheng-Yu Tsai, Stephen B. Howell, William G. Rice
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (6): 1177–1186.
DOI: https://doi.org/10.1158/1535-7163.MCT-17-1209
Published: 31 May 2018
View article
PDF
Includes: Supplementary data
Journal Articles

CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy

Adam Siddiqui-Jain, Joshua Bliesath, Diwata Macalino, Mayuko Omori, Nanni Huser, Nicole Streiner, Caroline B. Ho, Kenna Anderes, Chris Proffitt, Sean E. O'Brien, John K. C. Lim, Daniel D. Von Hoff, David M. Ryckman, William G. Rice, Denis Drygin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (4): 994–1005.
DOI: https://doi.org/10.1158/1535-7163.MCT-11-0613
Published: 08 April 2012
View article
PDF
Includes: Supplementary data
Journal Articles

Abstract C198: CX‐4945, a novel small molecule inhibitor of CK2 protein kinase, reduces hyperactivated Akt signaling and synergizes with Akt inhibitors in breast cancer cells

Denis Drygin, Josh Bliesath, Caroline Ho, Adam Siddiqui‐Jain, Sean O'Brien, Mayuko Omori, Nanni Huser, Chris Proffitt, Nicole Streiner, William G. Rice, Kenna Anderes
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C198.
DOI: https://doi.org/10.1158/1535-7163.TARG-09-C198
Published: 10 December 2009
View article